Effect of time and titer in convalescent plasma therapy for COVID-19
Article
[키워드] Abstract
all-cause mortality
benefit
clinical benefit
conditions
convalescent plasma
Convalescent plasma therapy
Coronavirus Disease (COVID)-19
COVID-19
COVID-19 mortality
Critical
disease stage
disease stages
early stage
early-stage COVID-19
Effect
evaluated
Follow-up
less
Meta-analysis
Mortality
non-randomized study
Patient
patients with COVID-19
plasma
plasma antibody
promote
provided
randomized clinical trial
RCT
RCTs
recipient
reduced
risk
selected
significantly
System
systematic review
systems medicine
the disease
Treatment
Virology
[DOI] 10.1016/j.isci.2021.102898 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.isci.2021.102898 PMC 바로가기 [Article Type] Article